World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
52
Citations
12030
World Ranking
4172
National Ranking
1618

Mark G. Thompson publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Mark G. Thompson sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 180 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Mark G. Thompson D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark G. Thompson sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 52 D-Index — 25th percentile

25% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Mark G. Thompson is affiliated with the Centers for Disease Control and Prevention in the United States. Their research focuses primarily on Medicine, with a strong emphasis on Epidemiology and Infectious Diseases. Their work also involves Health, Pulmonary and Respiratory Medicine, and Modeling and Simulation.

The scientist's research topics cover several areas related to viral infections and vaccines, including:

  • Influenza Virus Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Vaccine Coverage and Hesitancy
  • Respiratory viral infections research
  • COVID-19 Clinical Research Studies
  • COVID-19 epidemiological studies
  • Viral gastroenteritis research and epidemiology

Mark G. Thompson has contributed to numerous publications, with frequent appearances in specific venues such as:

  • MMWR Morbidity and Mortality Weekly Report
  • Vaccine
  • Clinical Infectious Diseases
  • The Journal of Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)

Recent notable papers authored by Thompson include:

  • Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021 (2021), MMWR Morbidity and Mortality Weekly Report
  • Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines (2021), New England Journal of Medicine
  • Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings (2021), New England Journal of Medicine
  • Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022 (2022), MMWR Morbidity and Mortality Weekly Report

Frequent collaborators include:

  • Allison L. Naleway
  • Manjusha Gaglani
  • Meredith G. Wesley
  • Eduardo Azziz-Baumgartner
  • Kempapura Murthy

Best Publications

  • Estimates of deaths associated with seasonal influenza - United States, 1976-2007.

    M. G. Thompson;D. K. Shay;H. Zhou;C. B. Bridges

  • Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.

    Mark G. Thompson;Jefferey L. Burgess;Allison L. Naleway;Harmony L. Tyner

  • Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

    Unknown

  • Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

    Unknown

  • Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.

    Mark G Thompson;Jefferey L Burgess;Allison L Naleway;Harmony Tyner

  • Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.

    Mark G Thompson;Edward Stenehjem;Shaun Grannis;Sarah W Ball

  • Influenza Vaccine Effectiveness in the 2011–2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates

    Suzanne E. Ohmit;Mark G. Thompson;Joshua G. Petrie;Swathi N. Thaker

  • Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

    Unknown

  • Influenza Vaccine Effectiveness in the United States During 2012–2013: Variable Protection by Age and Virus Type

    Huong Q. McLean;Mark G. Thompson;Maria E. Sundaram;Burney A. Kieke

  • Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022

    Unknown

  • Impact of Repeated Vaccination on Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons

    Huong Q. McLean;Mark G. Thompson;Maria E. Sundaram;Jennifer K. Meece

  • Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

    Unknown

  • Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains

    John J. Treanor;H. Keipp Talbot;Suzanne E. Ohmit;Laura A. Coleman

  • Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies.

    Marc Rondy;Nathalie El Omeiri;Mark M.G. Thompson;Alain Levêque

  • Influenza Vaccine Effectiveness in the Community and the Household

    Suzanne E. Ohmit;Joshua G. Petrie;Ryan E. Malosh;Benjamin J. Cowling

  • Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

    Unknown

  • Effectiveness of Seasonal Trivalent Influenza Vaccine for Preventing Influenza Virus Illness Among Pregnant Women: A Population-Based Case-Control Study During the 2010–2011 and 2011–2012 Influenza Seasons

    Mark G. Thompson;De-Kun Li;Pat Shifflett;Leslie Z. Sokolow;Leslie Z. Sokolow

  • Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016

    Mark G Thompson;Jeffrey C Kwong;Annette K Regan;Annette K Regan;Mark A Katz;Mark A Katz;Mark A Katz

  • Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.

    Peter J Embi;Matthew E Levy;Allison L Naleway;Palak Patel

  • Effectiveness of Influenza Vaccine Against Life-threatening RT-PCR-confirmed Influenza Illness in US Children, 2010–2012

    Jill M. Ferdinands;Jill M. Ferdinands;Lauren E. W. Olsho;Anna A. Agan;Niranjan Bhat

  • Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021.

    Shaun J. Grannis;Elizabeth A. Rowley;Toan C. Ong;Edward Stenehjem

  • Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines

    Mark G Thompson;Jefferey L Burgess;Allison Naleway;Harmony Tyner

  • Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010–11

    Mark G. Thompson;Allison Naleway;Alicia M. Fry;Sarah Ball

  • Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine.

    Jessie R. Chung;Brendan Flannery;Mark G. Thompson;Manjusha Gaglani

  • Frequency of Acute Respiratory Illnesses and Circulation of Respiratory Viruses in Households With Children Over 3 Surveillance Seasons

    Arnold S. Monto;Ryan E. Malosh;Joshua G. Petrie;Mark G. Thompson

  • Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Adults, 2011–2012 Influenza Season

    H. Keipp Talbot;Yuwei Zhu;Qingxia Chen;John V. Williams

  • Early estimates of seasonal influenza vaccine effectiveness - United States, January 2013

    Lisa Jackson;Michael L. Jackson;C. Hallie Phillips;Joyce Benoit

Frequent Co-Authors

Allison L. Naleway
Allison L. Naleway Kaiser Permanente
Manjusha Gaglani
Manjusha Gaglani Baylor College of Medicine
Alicia M. Fry
Alicia M. Fry Emory University
Arnold S. Monto
Arnold S. Monto University of Michigan–Ann Arbor
David K. Shay
David K. Shay Centers for Disease Control and Prevention
Jennifer K. Meece
Jennifer K. Meece Marshfield Clinic
Edward A. Belongia
Edward A. Belongia Marshfield Clinic
Richard K. Zimmerman
Richard K. Zimmerman University of Pittsburgh
Brendan Flannery
Brendan Flannery Centers for Disease Control and Prevention
Benjamin J. Cowling
Benjamin J. Cowling University of Hong Kong

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to various allied health and science career options. For graduates seeking roles beyond the laboratory, pursuing related online degrees can broaden skills and increase employability. One such path is becoming a Functional Medicine Nurse Practitioner, where knowledge of microbiology aids in understanding disease mechanisms. To learn more about earning potential, explore functional medicine nurse salary.

Another promising direction is health information management. With the growing importance of health data, professionals in this field command competitive wages. If you’re interested in healthcare data coding, consider becoming a Certified Professional Coder (CPC). Detailed insights on compensation and career trajectories are available at cpc salary.

Health Information Managers oversee the organization and security of patient data, ensuring compliance with healthcare standards. This role combines clinical knowledge with administration and technology. To understand their earning potential and job outlook, visit health information management jobs salary.

For those interested in pursuing these administrative and coding roles, accredited education is vital. Various online health information management degree programs are available to prepare students for industry challenges. Find reputable options through online health information management degree programs cahiim accredited.

Best Scientists Citing Mark G. Thompson

Trending Scientists